Theerut Luangmonkong

794 total citations
17 papers, 643 citations indexed

About

Theerut Luangmonkong is a scholar working on Hepatology, Epidemiology and Molecular Biology. According to data from OpenAlex, Theerut Luangmonkong has authored 17 papers receiving a total of 643 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Hepatology, 10 papers in Epidemiology and 6 papers in Molecular Biology. Recurrent topics in Theerut Luangmonkong's work include Liver physiology and pathology (10 papers), Liver Disease Diagnosis and Treatment (9 papers) and Drug-Induced Hepatotoxicity and Protection (3 papers). Theerut Luangmonkong is often cited by papers focused on Liver physiology and pathology (10 papers), Liver Disease Diagnosis and Treatment (9 papers) and Drug-Induced Hepatotoxicity and Protection (3 papers). Theerut Luangmonkong collaborates with scholars based in Thailand, Netherlands and Denmark. Theerut Luangmonkong's co-authors include Peter Olinga, Henricus A. M. Mutsaers, Su Suriguga, Geny M. M. Groothuis, Miriam Boersema, Warisara Parichatikanond, Supachoke Mangmool, Hitoshi Kurose, Dorenda Oosterhuis and Koert P. de Jong and has published in prestigious journals such as British Journal of Pharmacology, Biochemical Pharmacology and Nutrients.

In The Last Decade

Theerut Luangmonkong

16 papers receiving 635 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Theerut Luangmonkong Thailand 12 235 225 223 98 81 17 643
Weijian Huang China 15 178 0.8× 210 0.9× 244 1.1× 169 1.7× 77 1.0× 67 729
Akemi Tsutsui Japan 12 239 1.0× 213 0.9× 125 0.6× 121 1.2× 27 0.3× 27 574
Kengo Kawai Japan 11 342 1.5× 181 0.8× 130 0.6× 87 0.9× 34 0.4× 26 584
Lijie Sun China 18 413 1.8× 378 1.7× 173 0.8× 88 0.9× 87 1.1× 33 794
Ming Su China 15 320 1.4× 150 0.7× 381 1.7× 109 1.1× 141 1.7× 54 912
S. Galastri Italy 13 426 1.8× 334 1.5× 161 0.7× 150 1.5× 53 0.7× 17 790
Jesús García‐Bañuelos Mexico 14 175 0.7× 106 0.5× 157 0.7× 70 0.7× 59 0.7× 28 544
Eszter Trojnár United States 11 234 1.0× 142 0.6× 164 0.7× 118 1.2× 50 0.6× 16 647
Derrick Zhao United States 11 350 1.5× 163 0.7× 379 1.7× 99 1.0× 24 0.3× 21 727

Countries citing papers authored by Theerut Luangmonkong

Since Specialization
Citations

This map shows the geographic impact of Theerut Luangmonkong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Theerut Luangmonkong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Theerut Luangmonkong more than expected).

Fields of papers citing papers by Theerut Luangmonkong

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Theerut Luangmonkong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Theerut Luangmonkong. The network helps show where Theerut Luangmonkong may publish in the future.

Co-authorship network of co-authors of Theerut Luangmonkong

This figure shows the co-authorship network connecting the top 25 collaborators of Theerut Luangmonkong. A scholar is included among the top collaborators of Theerut Luangmonkong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Theerut Luangmonkong. Theerut Luangmonkong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Pandey, Sudhir, Supachoke Mangmool, Corina T. Madreiter‐Sokolowski, et al.. (2023). Exendin-4 protects against high glucose-induced mitochondrial dysfunction and oxidative stress in SH-SY5Y neuroblastoma cells through GLP-1 receptor/Epac/Akt signaling. European Journal of Pharmacology. 954. 175896–175896. 16 indexed citations
2.
Luangmonkong, Theerut, Warisara Parichatikanond, & Peter Olinga. (2023). Targeting collagen homeostasis for the treatment of liver fibrosis: Opportunities and challenges. Biochemical Pharmacology. 215. 115740–115740. 20 indexed citations
3.
Luangmonkong, Theerut, et al.. (2023). Hepatoprotective Efficacy of Cycloastragenol Alleviated the Progression of Liver Fibrosis in Carbon-Tetrachloride-Treated Mice. Biomedicines. 11(1). 231–231. 3 indexed citations
4.
Suriguga, Su, Mei Li, Theerut Luangmonkong, et al.. (2022). Distinct responses between healthy and cirrhotic human livers upon lipopolysaccharide challenge: possible implications for acute-on-chronic liver failure. American Journal of Physiology-Gastrointestinal and Liver Physiology. 323(2). G114–G125. 5 indexed citations
5.
Iswandana, Raditya, Su Suriguga, Theerut Luangmonkong, et al.. (2020). Murine Precision-cut Intestinal Slices as a Potential Screening Tool for Antifibrotic Drugs. Inflammatory Bowel Diseases. 26(5). 678–686. 9 indexed citations
6.
Beljaars, Leonie, Carian E. Boorsma, Catharina Reker‐Smit, et al.. (2020). Osteoprotegerin Is more than a Possible Serum Marker in Liver Fibrosis: A Study into Its Function in Human and Murine Liver. Pharmaceutics. 12(5). 471–471. 15 indexed citations
7.
Suriguga, Su, Theerut Luangmonkong, Henricus A. M. Mutsaers, Geny M. M. Groothuis, & Peter Olinga. (2020). Host microbiota dictates the proinflammatory impact of LPS in the murine liver. Toxicology in Vitro. 67. 104920–104920. 18 indexed citations
8.
Parichatikanond, Warisara, Theerut Luangmonkong, Supachoke Mangmool, & Hitoshi Kurose. (2020). Therapeutic Targets for the Treatment of Cardiac Fibrosis and Cancer: Focusing on TGF-β Signaling. Frontiers in Cardiovascular Medicine. 7. 34–34. 112 indexed citations
9.
Luangmonkong, Theerut, et al.. (2019). A Pathophysiological Model of Non-Alcoholic Fatty Liver Disease Using Precision-Cut Liver Slices. Nutrients. 11(3). 507–507. 21 indexed citations
10.
Luangmonkong, Theerut, Su Suriguga, Henricus A. M. Mutsaers, et al.. (2018). Targeting Oxidative Stress for the Treatment of Liver Fibrosis. Reviews of physiology, biochemistry and pharmacology. 175. 71–102. 219 indexed citations
11.
Luangmonkong, Theerut, Su Suriguga, Dorenda Oosterhuis, et al.. (2018). In vitro and ex vivo anti-fibrotic effects of LY2109761, a small molecule inhibitor against TGF-β. Toxicology and Applied Pharmacology. 355. 127–137. 14 indexed citations
12.
Luangmonkong, Theerut, Su Suriguga, Emilia Bigaeva, et al.. (2017). Evaluating the antifibrotic potency of galunisertib in a human ex vivo model of liver fibrosis. British Journal of Pharmacology. 174(18). 3107–3117. 72 indexed citations
13.
Westra, Inge M., Henricus A. M. Mutsaers, Theerut Luangmonkong, et al.. (2016). Human precision-cut liver slices as a model to test antifibrotic drugs in the early onset of liver fibrosis. Toxicology in Vitro. 35. 77–85. 54 indexed citations
14.
Iswandana, Raditya, Wouter T. van Haaften, Theerut Luangmonkong, et al.. (2016). Organ- and species-specific biological activity of rosmarinic acid. Toxicology in Vitro. 32. 261–268. 29 indexed citations
15.
Suriguga, Su, Theerut Luangmonkong, Emilia Bigaeva, et al.. (2016). LPS aggravates fibrosis only in the early onset but not in the end stage of liver fibrosis. University of Groningen research database (University of Groningen / Centre for Information Technology). 64. 1 indexed citations
16.
Luangmonkong, Theerut, Anna M. Leliveld, Igle J. de Jong, et al.. (2015). Precision-cut human kidney slices as a model to elucidate the process of renal fibrosis. Translational research. 170. 8–16.e1. 35 indexed citations
17.
Luangmonkong, Theerut. (2013). Pharmacotherapy of Trigeminal Neuralgia. 35(1). 14–20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Weijian Huang Breakdown of academic impact, for papers by Akemi Tsutsui Breakdown of academic impact, for papers by Kengo Kawai Breakdown of academic impact, for papers by Lijie Sun Breakdown of academic impact, for papers by Ming Su Breakdown of academic impact, for papers by S. Galastri Breakdown of academic impact, for papers by Jesús García‐Bañuelos Breakdown of academic impact, for papers by Eszter Trojnár Breakdown of academic impact, for papers by Derrick Zhao
Rankless by CCL
2026